Figure 1: Cyclin-dependent kinase 5 (Cdk5) downregulates peroxiredoxin-2 (Prx2) activity, leading to an accumulation of reactive oxygen species in the MPTP model of Parkinson's disease.

In a newly published study, researchers from the CSIR Institute of Genomics and Integrative Biology and collaborators further explored the potential of Cdk5 targeting as a therapeutic approach for ...